Compounds and methods for kinase modulation, and indications therefor

Patent metadata

Field	Value
Publication number	US-9617267-B2
Application number	US-201414216980-A
Country	US
Kind code	B2
Filing date	Mar 17, 2014
Priority date	Nov 18, 2009
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

Compounds of formula (I):

and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds of formula (I) or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

First claim

What is claimed is:

1. A method for alleviating or ameliorating one or more symptoms of melanoma or colon adenocarcinoma in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein
X is —N═;
Y is —N(R 3 )(R 4 ); wherein:
R 3 is hydrogen and R 4 is selected from the group consisting of (i) hydrogen, —OR 8 and lower alkyl optionally substituted with one or more R 11 ; (ii) cycloalkyl optionally substituted with one or more R 12 ; (iii) heterocycloalkyl optionally substituted with one or more R 13 ; (iv) aryl optionally substituted with one or more R 14 ; and (v) heteroaryl optionally substituted with one or more R 15 ; or
R 3 and R 4 are both lower alkyl; or
R 3 and R 4 combine with the nitrogen atom to which they are attached to form cycloalkylamino;

R 1 is selected from the group consisting of lower alkyl, haloalkyl, haloalkoxy, fluoro substituted lower alkyl, cycloalkyl optionally substituted with one or more R 7 , heterocycloalkyl, mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, aryl optionally substituted with one or more R 6 and heteroaryl optionally substituted with one or more R 7 ;
R 2 is hydrogen, fluoro, chloro, or lower alkyl optionally substituted with one or more fluorine;
each R 6 , when present, is independently selected from the group consisting of fluoro, chloro, —CN, —NO 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, —C(O)—O—R 18 , —N(H)—C(O)—R 19 , and heteroaryl optionally substituted with one or more lower alkyl;
each R 7 , when present, is independently selected from the group consisting of lower alkyl, fluoro substituted lower alkyl, lower alkoxy, —C(O)—O—R 20 , and heteroaryl optionally substituted with one or more lower alkyl;
R 8 is hydrogen, lower alkyl optionally substituted with one or more fluorine, or, when R 8 is a C 2-6 alkyl, said alkyl may optionally be substituted with one or more R 21 ; cycloalkyl optionally substituted with one or more R 21 , or heterocycloalkyl optionally substituted with one or more R 21 ;
each R 11 , when present, is independently selected from the group consisting of fluoro, —OH, lower alkoxy, fluoro substituted lower alkoxy, —NH 2 , mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, cycloalkyl optionally substituted with one or more R 12 , heterocycloalkyl optionally substituted with one or more R 13 , aryl optionally substituted with one or more R 14 , and heteroaryl optionally substituted with one or more R 15 ;
each R 12 , when present, is independently selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, —OH, lower alkoxy, fluoro substituted lower alkoxy, —NH 2 , mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, —N(H)—C(O)—R 22 , —N(H)—S(O) 2 —R 23 , C(O)—R 24 , and S(O) 2 —R 25 ;
each R 13 , when present, is independently selected from the group consisting of fluoro, —OH, lower alkoxy, fluoro substituted lower alkoxy, —NH 2 , mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, —N(H)—C(O)—R 26 , —N(H)—S(O) 2 —R 27 , C(O)—R 28 , S(O) 2 —R 29 , and lower alkyl optionally substituted with one or more R 30 ;
each R 14 and R 15 , when present, are independently selected from the group consisting of fluoro, chloro, —OH, —NH 2 , —CN, —NO 2 , —N(H)—C(O)—R 31 , —N(H)—S(O) 2 —R 32 , C(O)—R 33 , S(O) 2 —R 34 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, heterocycloalkylamino, aryl optionally substituted with one or more R 35 , and heteroaryl optionally substituted with one or more R 36 ;
each R 18 and R 20 , when present, are independently hydrogen, lower alkyl or fluoro substituted lower alkyl;
each R 19 , R 22 , R 23 , R 26 , R 27 , R 31 and R 32 , when present, are independently lower alkyl or fluoro substituted lower alkyl;
each R 21 , when present, is fluoro, —OH, lower alkoxy, —NH 2 , mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino;
each R 24 , R 25 , R 28 , R 29 , R 33 , and R 34 , when present, are independently lower alkyl, fluoro substituted lower alkyl, —OH, lower alkoxy, fluoro substituted lower alkoxy, —NH 2 , mono-alkylamino, di-alkylamino, cycloalkylamino, or heterocycloalkylamino;
each R 30 , when present, is independently fluoro, aryl optionally substituted with one or more R 35 or heteroaryl optionally substituted with one or more R 36 ;
each R 35 and R 36 , when present, are independently selected from the group consisting of fluoro, chloro, —OH, —NH 2 , —CN, —NO 2 , lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, mono-alkylamino, di-alkylamino, cycloalkylamino, and heterocycloalkylamino.

2. A method for alleviating or ameliorating one or more symptoms of melanoma or colon adenocarcinoma in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof as set forth in claim 1 and another drug.

3. A method for alleviating or ameliorating one or more symptoms of melanoma or colon adenocarcinoma in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the method further comprises administering another drug.

5. The method of claim 3 , wherein the method is for alleviating or ameliorating one or more symptoms of melanoma.

6. The method of claim 3 , wherein the method is for alleviating or ameliorating one or more symptoms of colon adenocarincoma.

Assignees

• Plexxikon Inc

Inventors

• Ibrahim Prabha N
• Spevak Wayne
• Cho Hanna
• Shi Songyuan
• Zhang Chao
• Zhang Ying

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title